Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy not identical
Complete response · people with chronic lymphocytic leukaemia
Anti‐leukaemic therapy with alemtuzumab showed no clear difference in complete response rate compared with anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy… (moderate certainty).
1 finding from 1 review
- RR 0.85 [0.67, 1.08]2 studies · 170 participantsModerate